Since Campylobacter pylori was first isolated from gastric biopsies in 1983, the strong association between the presence of this organism and the histopathologic findings of antral gastritis has been confirmed by numerous studies that have been conducted worldwide (3, 10, 14) . Results of studies in which the use of antimicrobial agents in the treatment of nonulcer dyspepsia and peptic ulcer disease associated with C. pylori have been examined have not been conclusive, but eradication of the organism has been reported to be associated with resolution of the gastric mucosal inflammation (7, 9, 12, 14) . The fluoroquinolones comprise a group of oral antimicrobial agents with several attractive characteristics, including broad-spectrum activity against aerobic and facultative bacteria, good tissue penetration, and a low incidence of adverse effects (6, 18) . In this study, we determined the in vitro susceptibility of C. pylori to several recently introduced fluoroquinolones and other oral antimicrobial agents that have been considered to be of potential value in the treatment of C. pylori-associated gastritis.
The MICs were determined by an agar dilution technique by using Mueller-Hinton agar (GIBCO Diagnostics, Madison, Wis.) that was supplemented with 5% lysed horse blood and 2% Vitox (Oxoid Ltd., Basingstoke, England) and that contained antibiotics in concentrations ranging from 0.002 to 128 ,ug/ml. All The susceptibilities of the C. pylori isolates to the antimicrobial agents tested, expressed as the concentrations required to inhibit 50 and 90% of the strains, are given in Table  1 . Ciprofloxacin was the most active of the quinolones in vitro (MIC for 90% of strains tested, 0.5 ,ug/ml). All C. pylori strains were also moderately susceptible to two newer fluoroquinolones, fleroxacin and lomefloxacin, whereas norfloxacin, pefloxacin, and enoxacin demonstrated more modest activities. C. pylori was susceptible to ampicillin, erythromycin, tetracycline, and nitrofurantoin; but it was resistant to nalidixic acid, cinoxacin, and trimethoprimsulfamethoxazole, as has been reported previously (1, 5, 8,
11, 13, 15, 17).
It is not yet known whether antimicrobial therapy for gastritis or peptic ulcer disease would lead to more rapid symptomatic improvement, endoscopic healing, or lower risk of relapse. The in vitro activities of some of the fluoroquinolones suggest that they may be useful either alone or in combination with conventional antiulcer medications in the treatment of gastritis or peptic ulcer disease associated with C. pylori. However, two recent reports have dampened enthusiasm for the role of these agents in the treatment of C. pylori-associated gastritis. Glupczynski et al. (4) described five patients who were treated with ofloxacin and ranitidine, in whom resistance to ofloxacin developed during treatment; cross-resistance to other fluoroquinolones was also observed. Stone and co-workers (16) have reported a failure to eradicate C. pylori in 9 of 14 patients with 
